OptimizeRx Q1 revenue +51% to $19.7M; Adj EBITDA improves to $(0.3)M; reaffirms FY guidance

OptimizeRx Corp

2024-Q1 EPS reported -$0.38 revenue$19,690,000

Revenue $19.7M, +51% YoY; gross profit $12.2M, +64% YoY.
GAAP net loss $(6.9)M ($0.38/share); Non-GAAP net loss $(2.0)M ($0.11/share).
Adjusted EBITDA improved to $(0.3)M from $(2.2)M a year ago.
Won 9 DAAP (AI-platform) deals in Q1; Net Revenue Retention 116% vs 86%.
Reiterated FY2024 guidance: revenue at least $100M, Adj EBITDA at least $11M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OptimizeRx Corp reported financial results for the first quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 14, 2024, OptimizeRx Corporation issued a press release announcing its financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

OptimizeRx Corp filing history →

Source: SEC EDGAR

accession 0001213900-24-042937

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.